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Chapter 4
Urinary Vitamin D Binding Protein: a Potential Novel
Marker of Renal Interstitial Inflammation and Fibrosis
Katarina Mirkovic´, Carolina R.C. Doorenbos, Wendy A. Dam, Hiddo J.
Lambers Heerspink, Maartje C.J. Slagman, Ferdau L. Nauta, Andrea B.
Kramer, Ronald T. Gansevoort, Jacob van den Born, Gerjan Navis, Martin
H. de Borst




Non-invasive tubulointerstitial damage markers may allow better titration and
monitoring of renoprotective therapy. We investigated the value of urinary vitamin D
binding protein excretion (uVDBP) as a tubulointerstitial inflammation and fibrosis
marker in adriamycin rats, and tested whether uVDBP parallels renal damage and
responds to therapy intensification in humans. In adriamycin (ADR) rats, uVDBP was
strongly elevated vs controls (CON) already 6 wks after nephrosis induction (ADR:
727±674 [mean±SD] vs CON: 9±12 µg/d, p<0.01), i.e. before onset of pre-fibrotic
and inflammatory tubulointerstitial damage, and at all following 6-wk time points
until end of follow up at 30 wks (ADR: 1403±1026 vs CON: 206±132 µg/d, p<0.01).
In multivariate regression analysis, uVDBP was associated with tubulointerstitial
macrophage accumulation (standardized beta=0.47, p=0.01) and collagen III expression
(standardized beta=0.44, p=0.02) independently of albuminuria. In humans, uVDBP
was increased in 100 microalbuminuric subjects (44±93 µg/d) and in 47 CKD patients
with overt proteinuria (9.2±13.0 mg/d) compared to 100 normoalbuminuric subjects
(12±12 µg/d, p<0.001). In CKD patients, uVDBP responded to intensification of reno-
protective therapy (ACEi+liberal sodium: 9.2±13.0 mg/d vs dual RAAS blockade+low
sodium: 2747±4013, p<0.001), but remained still >100-fold increased during maximal
therapy vs normoalbuminurics (p<0.001), consistent with persisting tubulointerstitial
damage. UVDBP was associated with tubular and inflammatory damage markers KIM-1
(standardized beta=0.52, p<0.001), beta-2-microglobuline (st.beta=0.45, p<0.001),
cystatin C (st.beta = 0.40, p<0.001), MCP-1 (st.beta=0.31, p<0.001) and NGAL
(st.beta=0.20, p=0.005), independently of albuminuria. UVDBP may be a novel urinary
biomarker of tubulointerstitial damage. Prospectively designed studies are required to
validate our findings and confirm its relevance in the clinical setting.
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4.1 Introduction
The severity of renal interstitial fibrosis has consistently been identified as the strongest
predictor of subsequent progressive renal function loss 1. Early profibrotic changes, on
the other hand, might still be reversible 2. Reliable, non-invasive assessment of tubu-
lointerstitial damage would therefore be of great value in development and monitoring of
renoprotective therapy 3.
Vitamin D binding protein (VDBP), also known as group-specific component (GC),
is a glycosylated alpha-globulin of 58 kDa 4. Its main function is to transport vitamin D
metabolites through the circulation. VDBP is filtered by the glomerulus and subsequently
reabsorbed by proximal tubular cells through receptor-mediated uptake. This process is
crucial for retrieval of vitamin D for activation by 1-alpha hydroxylase, which is abun-
dantly present in proximal tubular cells 5. Tubular reabsorption of VDBP is mediated by
megalin and cubulin receptors 6, 7. Since receptor-mediated uptake of proteins such as
VDBP is energy-consuming, tubular injury would be expected to result in urinary VDBP
(uVDBP) loss 8. Indeed, a previous small study suggested that uVDBP is grossly elevated
in CKD patients and can be reversed by antiproteinuric treatment 9. In diabetic subjects,
uVDBP is increased compared to non-diabetics, especially when albuminuria is present 10.
Whether uVDBP is related to the extent of tubulointerstitial damage has not specifically
been addressed.
We therefore explored the potential role of uVDBP as a marker of tubulointerstitial
damage in two independent settings. First we studied the time course of uVDBP in
relation to the development of interstitial fibrosis and inflammation in the rat model
of adriamycin-induced nephropathy at several time points after induction of nephrosis.
We used this model as its protracted time course in the development of renal structural
damage allows good resolution over time. Subsequently, in human subjects we addressed
the relation between uVDBP and established tubular damage markers in patients with
various stages of renal damage, i.e microalbuminuria and overt proteinuria, respectively,
as compared to normoalbuminuric controls. We also studied whether intensification of
anti-proteinuric therapy would reduce urinary VDBP excretion.
4.2 Materials and Methods
4.2.1 Ethics Statement
Male Wistar rats (n=90 ) were housed in a temperature and light controlled room, with
free access to food and water. All rats received normal standard rat chaw containing 2000
UI/kg of vitamin D3.Twenty four hour urine was collected every two weeks by housing in
metabolic cages. Surgical procedures took place under isoflurane anesthesia. At the end
of the study, the abdominal aorta was cannulated and kidneys were perfused in situ with
saline during removal. Proteinuria was measured on a BNII third-generation nephelometer
(Dade Behring, Mannheim, Germany).
Rats were assigned to two groups: unilateral adriamycin proteinuric (UAP) nephropa-
thy (n=60 ), or controls (n=30 ) 11. Unilateral adriamycin nephrosis was induced by
temporarily clipping the left renal artery through a midline abdominal incision, followed
by adriamycin (1.5 mg/kg) injection via the tail vein, as described previously 11. After 12
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min, when adriamycin has been cleared from the circulation 12, the clamp was removed.
Control rats underwent the same procedure but were injected with saline. To study renal
damage over time, groups of 12 UAP and six control rats were sacrificed at weeks 6, 12,
18, 24, and 30 after surgery. Kidneys were fixed in formalin and embedded into paraffin.
4.2.2 Patients
For clinical studies, 100 normoalbuminuric and 100 microalbuminuric subjects were ran-
domly selected from Prevention of REnal and Vascular ENd stage Disease (PREVEND),
a prospective cohort study investigating the association of albuminuria with renal and
cardiovascular disease progression in the general population 13. In short, between 1997
and 1998, participants of the PREVEND cohort were recruited from 40,856 inhabitants
of the city of Groningen, the Netherlands. To obtain a cohort enriched for the presence of
elevated albuminuria levels, selection was based on the albumin concentration in a spot
morning urine sample. The baseline screening round was completed in by 8,592 partic-
ipants. Thereafter, participants were invited to visit an outpatient clinic for a medical
examination at approximately 3-year intervals. For the present study, data obtained at
baseline were used. Anthropometrical, clinical and biochemical data were collected as re-
ported previously 13. Glomerular filtration rate was estimated (eGFR) with the modified
Modification of Diet in Renal Disease (MDRD) formula, taking into account gender, age,
race, and serum creatinine concentration. At each screening round two 24-h urine samples
were collected after thorough oral and written instructions on how to collect these samples.
Urinary albumin concentration was determined in fresh urine samples by nephelometry
with a threshold of 2.3 mg/L and intra- and inter-assay coefficients of variation (CV) of
2.2 and 2.6%, respectively (BNII; Dade Behring Diagnostic, Marburg, Germany). Albu-
minuria is given as the mean of the two 24-hour urine albumin excretion measurements.
Urine samples for biomarker measurements were stored at −20°C; plasma samples were
stored at −80°C. VDBP was measured in urine samples collected at baseline from 100
randomly selected normo- and microalbuminuric subjects.
Furthermore, urine samples and clinical data were used from a previously performed
randomized controlled trial in patients with established non-diabetic chronic kidney dis-
ease (CKD) 14. Briefly, in this study, 52 patients (IgA nephropathy, n=15 ; FSGS, n=14 ;
membranous nephropathy, n=7 ; hypertensive nephropathy, n=6 ; minimal change dis-
ease, n=2 ; unknown, n=8 ) were subjected to a protocol including a 6-week study period
with standard anti-proteinuric therapy (i.e. the angiotensin converting enzyme (ACE) in-
hibitor lisinopril 40 mg/day and a regular sodium diet of 200 mmol Na+ per day), and
another 6-week study period with intensified anti-proteinuric therapy (lisinopril 40 mg/day
combined with the AT1 receptor blocker valsartan 320 mg/day and a low sodium diet,
target 50 mmol Na+ per day). At the end of each study period, clinical data were recorded
and blood and urine samples were collected for analysis. Data and urine samples from
both study periods were available for 47 patients for the current post-hoc analyses 14.
4.2.3 Measurement of Urinary VDBP and Other Biomarkers
After thawing urine and plasma samples were vortexed and subsequently centrifuged
(14.000 rpm). The supernatant was used for measurements. Human VDBP was measured
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with a commercially available sandwich ELISA (Immundiagnostik, catalog # K2314, Ben-
sheim, Germany), according to the manufacturer’s instructions. Briefly, plasma (diluted
1:40000) or urine (diluted 1:2–1:5 for controls and 1:10–1:3000 for the other groups de-
pending on the concentration of VDBP) was incubated in a microtiter plate coated with
polyclonal anti-VDBP antibodies for one hour. Subsequently, a polyclonal peroxidase-
labeled rabbit-anti-VDBP detection antibody was added and incubated for one hour.
After washing, tetramethylbenzidine was added as substrate for 15 minutes. After adding
a stop solution, absorbance at 450 nm was measured by a spectrophotometer (BenchMark
Plus, Bio-Rad Laboratories, Veenendaal, The Netherlands). Using a standard curve gen-
erated with VDBP protein as provided by the manufacturer, final VDBP concentrations
were calculated. The detection limit of this ELISA is 1.23 ng/ml; intra-assay CV <5.0%
for 16 replicate determinations at concentrations of 24.2 and 42.9 mg/dl and inter-assay
CV <12.7% for a concentration of 19.3 mg/dl in 14 different assays on two different lots;
recovery ranges from 85–116% and linearity was acceptable (r2 = 0.998). Rat VDBP was
measured using another commercially available ELISA kit (Alpco, Salem, NH), according
to the manufacturer’s instructions. Detection limit as provided by manufacturer: 3.125
ng/ml, range 3.125–100 ng/ml. VDBP excretion was calculated from the VDBP concen-
tration in urine collected over a 24-hour period.
The established proximal tubular damage markers kidney injury molecule-1 (KIM-
1), beta-2-microglobulin and cystatin C as well as the inflammation markers mono-
cyte chemoattractant protein-1 (MCP-1) and neutrophil gelatinase associated lipocalin
(NGAL) were determined in urine and plasma as described previously 15,16. Briefly, we
developed direct sandwich-enzyme-linked immunosorbent assays using monoclonal coat-
ing antibodies and labeled polyclonal detection antibodies on a Maxisorp plate (Nunc,
Denmark). The concentration of the analyte was determined spectrophotometrically
by conversion of o-phenylenediamine by a horseradish peroxidase label. KIM-1, beta-
2-microglobulin, NGAL and MCP-1 antibodies were obtained from R&D systems (Min-
neapolis, USA). The intra-assay coefficients of variation (CV) of these ELISA’s were 7.4%,
9.7%, 6.8% and 6.8% respectively. Cystatin C was measured by nephelometry (reagents
obtained from Siemens [Marburg, Germany]). Samples were diluted to obtain optimal
concentration for measurement. All samples were measured in duplicate.
4.2.4 Immunohistochemistry
Paraffin sections (4 µm) were deparaffinized and stained with periodic acid-Schiff (PAS)
to evaluate focal glomerulosclerosis (FGS). For immunostaining, sections were subjected
to heat-induced antigen retrieval by overnight incubation in 0.1M Tris/HCl buffer (pH
9) at 80°C. An automated staining system (DAKO Autostainer, Carpinteria, CA, USA)
was used to obtain comparable staining results for all slides. Alpha-smooth muscle actin
and monocytes/macrophages were detected using murine monoclonal antibodies (α-SMA:
clone 1A4, Sigma, St. Luis, MO, USA, and ED1: Serotec Ltd, Oxford, UK, respectively)
for 60 min at room temperature. Binding was detected using sequential incubations
with peroxidase-labeled rabbit anti-mouse and peroxidase-labeled goat anti-rabbit anti-
bodies (Dakopatts, Glostrup, Denmark) for 30 min. Collagen III was detected using
rabbit polyclonal antibody (Col III, Biogenesis, Ltd, Poole, UK) for 60 minutes at room
temperature followed by sequential incubations with peroxidase-labeled goat anti-rabbit
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and peroxidase-labeled rabbit anti-goat antibodies (Dakopatts, Glostrup, Denmark) for
30 min. Peroxidase activity was developed by using 3,3’- diaminobenzidine tetrachloride
containing 0.03% H2O2 for 10 minutes. Counterstaining was performed using Mayer’s
hematoxylin 17.
4.2.5 Quantification of Renal Damage
Sections were examined in a blinded fashion. The severity of FGS was assessed on PAS
sections by semi-quantitative scoring of 50 glomeruli per slide on a scale of 0 to 4. FGS
was scored positive if collapse of capillary lumina, mesangial matrix expansion, hyalinosis
and adhesion of the glomerular tuft to Bowman’s capsule were simultaneously present. If
25% of glomerulus was affected, a score of 1 was adjudged, 50% was scored as 2, 75% as
3, and 100% as 4. The ultimate score per animal was obtained by multiplying the degree
of change by the percentage of glomeruli with the same degree of injury and addition of
these scores.
The extent of interstitial α-SMA and collagen III protein expression was measured us-
ing computer-assisted morphometry. Fifty cortical interstitial fields (200× magnification)
were measured with exclusion of arteries and glomeruli and percentage of the stained area
was determined. The ultimate score was calculated by the average of all fields per sec-
tion. Glomerular and interstitial macrophages were counted manually in respectively 50
glomeruli and 50 interstitial fields per section and the mean number per section/animal
was calculated.
4.2.6 Statistical Analyses
Analyses were performed with PASW Statistics 18.0.3 (SPSS, Armonk, NY). Parametric
variables are expressed as mean ± standard deviation (SD), whereas non-parametric vari-
ables are given as median (interquartile range). Differences between groups were tested
using student’s t-test or Mann-Whitney test where appropriate. Linear regression analysis
was performed to address the association between uVDBP and parameters of tubuloin-
terstitial damage, both at the time point of sacrifice. These associations were studied
in univariate models as well as in multivariate models adjusting for albuminuria to ad-
dress whether the relation between uVDBP and parameters of structural renal damage
depended on albuminuria. In these analyses, all adriamycin animals were considered to-
gether in a regression model adjusted for the timepoint after induction of nephrosis. This
allowed us to study the relation between uVDBP and renal damage parameters across
the spectrum of renal damage. Distribution of the variables was verified by Q-Q plots
and histograms. Non-normally distributed variables were transformed to the natural log
before entering the regression model. For all analyses a two-sided p<0.05 was considered
statistically significant.
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4.3 Results
4.3.1 Rat Unilateral Adriamycin Model
The relation between urinary VDBP excretion and structural renal abnormalities in
chronic kidney disease was addressed in the rat unilateral adriamycin nephropathy model.
This model is characterized by relatively mild albuminuria as only one kidney is affected,
followed by the development of renal inflammation, focal glomerulosclerosis (FGS), and
tubulointerstitial fibrosis in the affected kidney without concomitant changes in renal func-
tion (Table 4.1), as described in detail previously 18. Massive urinary VDBP excretion was
already present at 6 weeks after adriamycin injection (Figure 4.1A, (adriamycin: 727±674
µg/d vs controls: 9±12 µg/d, p<0.01), when interstitial alpha-smooth muscle actin (α-
SMA) and collagen III expression as well as interstitial macrophage accumulation were
still similar to control kidneys (Figure 4.1B, Figure 4.2). Also at all other time points
until end of follow up at 30 wks (ADR: 1403±1026 vs CON: 206±132 µg/d, p<0.01),
VDBP remained elevated in adriamycin rats compared to controls at the same time point
after start of the experiment.
The relation between uVDBP and renal damage markers were subsequently addressed
in multivariate regression analysis where all adriamycin rats were analyzed together and
data were adjusted for the time point of sacrifice. This approach allowed us to address the
relation between uVDBP and renal damage markers across the spectrum of renal damage,
analyzing each animal once (at the time of sacrifice). UVDBP was strongly associated with
interstitial expression of the pre-fibrotic marker α-SMA and with collagen III expression,
as well as with interstitial macrophage accumulation (Table 4.2). UVDBP was also asso-
ciated with albuminuria and FGS, but not glomerular macrophage influx. Subsequently
the associations between uVBDP and the parameters of renal damage were adjusted for
albuminuria in multivariate regression analysis. UVDBP remained significantly associ-
ated with α-SMA and collagen III as well as with interstitial macrophage accumulation,
independently of albuminuria. The association between uVDBP and FGS, however, did
depend on albuminuria (Table 4.2). Together, these data suggest that uVDBP is al-
ready increased before the onset of (early) tubulointerstitial fibrosis and inflammation,
and uVDBP increases further in association with increasing tubulo-interstitial damage
severity.
4.3.2 Clinical Studies
We further characterized urinary VDBP excretion in the clinical setting. Table 4.3 shows
baseline parameters at inclusion for the study groups: subjects with microalbuminuria
(n=100 ) and normoalbuminuric controls (n= 100), both derived from a general popu-
lation cohort study, and subjects with non-diabetic chronic kidney disease (CKD) with
overt proteinuria (n=47 ). The CKD group was studied during two different treatment
periods of 6 weeks, one period with an ACE inhibitor under a liberal sodium diet, and one
period with intensified renoprotective therapy: dual renin-angiotensin-aldosterone system
(RAAS) blockade (ACE inhibitor and AT1 receptor blocker) under dietary sodium restric-
tion. As shown in Figure 4.3, uVDBP was low in normoalbuminuric subjects, higher in
microalbuminurics, and highest in patients with established CKD (p<0.001). In CKD pa-
tients, intensification of anti-proteinuric therapy (dual RAAS blockade and dietary sodium
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Figure 4.1: Urinary vitamin D binding protein (uVDBP) and albuminuria levels, and structural
renal changes over time in adriamycin and control rats. A. Graphs illustrating the development
of albuminuria (orange) and uVDBP (purple) over time in the unilateral adriamycin nephropathy
model and in sham-operated control animals. B. Development of tubulointerstitial damage as
reflected by interstitial α-smooth muscle actin (blue bars) and collagen III staining (green bars),
and interstitial macrophage accumulation (red bars) in adriamycin rats (dark bars) and controls
(light bars).
restriction) reduced uVDBP from median 4 mg/day to 1 mg/24 h (p<0.001); however
urinary VDBP was still >100-fold increased as compared to normoalbuminuric subjects
(median 7 µg/24 h; p<0.001 vs CKD+ACEi+ARB+low sodium), consistent with persis-
tent tubulointerstitial damage despite maximal therapy. When uVDBP was normalized
for albuminuria, differences remained similar: patients with normoalbuminuria 0.44 [0.22–
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Table 4.1: Group characteristics from the experimental study.
Table 4.2: Associations of urinary VDBP with renal histological parameters in the affected
kidney in the rat unilateral adriamycin nephropathy model.
0.77] µg/mg; microalbuminuria 0.62 [0.34–1.18] µg/mg; established CKD+ACEi+liberal
sodium: 2.44 [1.02–4.51] µg/mg, p<0.001; CKD+ACEi+ARB+low sodium 1.87 [0.92–
2.97] µg/mg, p<0.05. Plasma VDBP levels were similar in all groups (normoalbuminuria:
31 [25–42] µg/l; microalbuminuria: 32 [24–43] µg/l; CKD+ACEi+liberal sodium: 39 [38–
47] µg/l; CKD+ACEi+ARB+low sodium: 38 [34–42] µg/l; p = NS).
4.3.3 VDBP is Associated with Established Renal Damage
Markers
The relation between uVDBP and established markers of proximal tubular damage and re-
nal inflammation was further addressed in normo- and microalbuminuric subjects (n=200 ).
UVDBP was strongly associated with urinary KIM-1, beta-2-microglobulin and cystatin
C (Table 4.4 and Figure 4.4). Of interest, urinary VDBP was also associated with urinary
excretion of the inflammation markers MCP-1 and NGAL. These associations were inde-
pendent of albuminuria (Table 4.4, Figure 4.4). Accordingly, the VDBP/albuminuria ratio
was associated with KIM-1 (r = 0.50, p<0.001), beta-2-microglobulin (r = 0.26, p<0.001),
cystatin C (r = 0.26, p = 0.001), MCP-1 (r = 0.19, p = 0.009) and NGAL (r = 0.16, p = 0.01).
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Table 4.3: Baseline characteristics of general population cohort.
Table 4.4: Associations of VDBP with renal damage markers across the clinical cohorts.
Using VDBP/proteinuria ratios yielded similar results. None of the urinary biomarker
levels were associated with their plasma levels (data not shown). Neither urinary VDBP
excretion nor albuminuria was associated with eGFR.
4.4 Discussion
To our knowledge this study is the first to demonstrate that urinary VDBP is a biomarker
of tubulointerstitial damage, independent of albuminuria, in an animal model of renal dam-
age. In humans, urinary VDBP increased along with the severity of renal damage, was
associated with tubular and inflammatory markers independently of albuminuria, and
responded to intensification of renoprotective therapy. Yet, the current cornerstone of
68
Urinary Vitamin D Binding Protein
Figure 4.2: Representative photographs of renal damage markers in adriamycin-exposed and
control kidneys. Interstitial α-SMA increased progressively in proteinuric kidneys during follow
up (A, B). α-SMA was located around dilated tubules (arrows) and in blood vessels (arrowheads).
In control kidneys at week 30, only very limited expression of interstitial α-SMA was present (C).
Interstitial macrophage influx increased in ADR animals (D, E). ED-1 positive cells were found
mostly around damaged tubules (arrows) and sporadically present in the interstitium of control
kidneys (F). Immunostaining of collagen III was found in ADR animals (G, H; arrows), and rarely
in controls (I).
renoprotective therapy (maximal RAAS blockade combined with dietary sodium restric-
tion) did not achieve normalization of uVDBP, suggesting persistent tubulointerstitial
damage in CKD patients. These findings suggest that uVDBP could be developed into a
non-invasive urinary marker to monitor tubulointerstitial inflammation and fibrosis.
The urinary loss of VDBP in the setting of renal damage has been reported previously
in a rat nephrotoxicity model using urinary proteomics analysis 19, as well as in the
setting of chronic kidney disease 9, 10, but its mechanism has not been documented.
Interestingly, we found that uVDBP was strongly and consistently elevated in a very
early stage of adriamycin-induced nephropathy, even before a detectable increase in the
early pre-fibrotic marker α-SMA. UVDBP was also strongly associated with markers of
both early and late tubulointerstitial fibrosis (α-SMA and collagen III, respectively) in
linear regression analysis adjusted for the time after induction of nephrosis. Of interest,
VDBP excretion was also associated with interstitial inflammation, even independent of
albuminuria. Its potential as a marker of interstitial inflammation renders VDBP an even
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Figure 4.3: Urinary vitamin D binding protein (uVDBP) levels in patients with normoalbu-
minuria, microalbuminuria, and overt proteinuria. Box-whisker plots indicating the median,
interquartile range, and range of 24-h uVDBP per patient category: general population with
normoalbuminuria, general population with microalbuminuria, chronic kidney disease with overt
proteinuria treated with ACE inhibitor and liberal sodium diet, and chronic kidney disease with
overt proteinuria treated with ACE inhibitor+ARB+low sodium diet. UVDBP increased with
albuminuria (first three groups, p<0.001) and responded to intensification of anti-proteinuric
treatment (two last groups, p<0.001).
more interesting candidate biomarker. The fact that these associations persisted after
adjustment for albuminuria suggests that not only protein overload of the megalin/cubulin
complex plays a role in urinary VDBP loss. Rather, damaged tubular epithelial cells in
areas of tubulointerstitial fibrosis may no longer be able to handle VDBP, resulting in gross
VDBP loss into the urine. Indeed, major factors involved in tubulointerstitial fibrosis and
inflammation (e.g. TGF-beta and angiotensin II) negatively regulate receptor-mediated
endocytosis 20, 21.
We and others reported previously that uVDBP is increased in patients with chronic
kidney disease 9, 10, and that it can be modulated by anti-proteinuric treatment in patients
9, although our previous study was of limited sample size. In accordance with our previous
study 9, plasma VDBP levels were similar among normo- and microalbuminuric subjects
and CKD patients. Our study is in line with previous work showing that uVDBP increases
with increasing severity of diabetic nephropathy 10. Although the combination of optimal
RAAS blockade and dietary sodium restriction, an intervention considered optimal for
renoprotection, considerably reduced VDBP excretion, it remained >100-fold increased
as compared to healthy normoalbuminuric subjects. This suggests that tubulointerstitial
damage, considered the final common pathway towards end-stage renal disease (ESRD),
persists to a considerable extent despite current best available therapy. This is in line with
previous preclinical studies showing progression of pre-fibrotic tubulointerstitial lesions –
in spite of optimal reduction of proteinuria – by ACE inhibition and (very strict) dietary
sodium restriction 22. This may explain at least partly why many patients progress to
ESRD despite optimal RAAS blockade and dietary sodium restriction – although progres-
sion to ESRD is more common in those with high sodium intake 23.
Limitations of our study include the lack of histopathological data in humans to which
uVDBP could be related, and the largely cross-sectional design. Although in the animal
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Figure 4.4: Urinary vitamin D binding protein (uVDBP) and established renal tubular damage
markers in patients with renal damage. (continues on the next page)
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Figure 4.4: (continued) Urinary vitamin D binding protein (uVDBP) and established renal
tubular damage markers in patients with renal damage. Box-whisker plots illustrating the relation
between uVDBP and established renal tubular damage markers kidney injury molecule-1 (KIM-
1) (A), beta-2-microglobulin (B2M) (B), Cystatin C (CysC) (C) and monocyte chemoattractant
protein-1 (MCP-1) (D) in normo- and microalbuminuric subjects (both n=100). The uVDBP is
presented per quartile of the established renal damage marker studied. In all panels (A-D), the left
four box whisker plots represent the unadjusted VDBP excretion, and the right four box whisker
plots represent the uVDBP adjusted for albuminuria. All biomarkers are positively associated
with uVDBP, also when VDBP was adjusted for albuminuria (p<0.001, Kruskal Wallis).
studies uVDBP was tracked over time, this study does not contain prospective data allow-
ing validation of uVDBP as a biomarker. Urine samples were stored at −20°C which may
have influenced VDBP stability. Strengths of our study, on the other hand, include the use
of 24 h-urine samples in both human and the animal studies, and the equivocal findings in
patients and animals, using two different ELISA systems to detect urinary urinary VDBP.
Therefore we believe that our observations can be considered hypothesis-generating and
warrant further studies on the predictive value of urinary VDBP in a well-characterized
cohort with longitudinal follow-up, as well as studies addressing the associations between
uVDBP and histopathological findings in the clinical setting. Furthermore it would be
interesting to study uVDBP after kidney transplantation, where interstitial fibrosis also
has an important prognostic role.
In conclusion, we demonstrated that urinary VDBP excretion is increased early after
renal injury, and is associated with tubulointerstitial inflammation and fibrosis indepen-
dently of albuminuria in a rat model of proteinuric nephropathy. In humans, uVDBP
increased with increasing severity of renal damage, and responded to renoprotective ther-
apy. Yet, persisting uVDBP at >100 times above normal suggested persistent tubuloin-
terstitial damage despite optimal renoprotective therapy. Future studies should address
whether urinary VDBP has predictive value for progression of renal function loss, and
whether uVDBP is a more suitable early marker of tubulointerstitial damage than the
tubular biomarkers currently available, to better guide therapy in chronic kidney disease
patients.
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